SCHEMBL66069

SCHEMBL66069

O=C(COc1ccc(F)c(Cl)c1)N1CCC(S(=O)(=O)N2CCCC2)C1

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.47
RAB9A P51151 5/20 0.47
KMT2A Q03164 3/20 0.47
NPC1 O15118 3/20 0.47
MAPT P10636 3/20 0.46
HPGD P15428 2/20 0.46
POLB P06746 1/20 0.46
SMN1; SMN2 Q16637 6/20 0.45
ALDH1A1 P00352 3/20 0.45
GAA P10253 1/20 0.45
LMNA P02545 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.44
ATF4 P18848 2/20 0.44
PKM P14618 2/20 0.43
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL65663 0.82 ALDH1A1 (0.46) TDP1RAB9AKMT2ANPC1MAPT
SCHEMBL56480 0.80 SMN1; SMN2 (0.53) TDP1RAB9ANPC1MAPTHPGD
SCHEMBL65760 0.80 SMN1; SMN2 (0.50) TDP1RAB9ANPC1MAPTHPGD
SCHEMBL57050 0.80 KMT2A (0.47) RAB9AKMT2ANPC1MAPTPOLB
SCHEMBL8243715 0.79 SMN1; SMN2 (0.41) RAB9ANPC1MAPTSMN1; SMN2ALDH1A1
SCHEMBL66545 0.77 ALDH1A1 (0.48) RAB9AKMT2AMAPTPOLBSMN1; SMN2
SCHEMBL56987 0.76 KMT2A (0.51) KMT2APOLBSMN1; SMN2ALDH1A1GAA
SCHEMBL8243869 0.73 SMN1; SMN2 (0.43) RAB9AKMT2ANPC1MAPTHPGD
SCHEMBL19702678 0.71 SMN1; SMN2 (0.44) TDP1RAB9AKMT2AMAPTPOLB
SCHEMBL19702694 0.70 ALDH1A1 (0.48) RAB9AKMT2AMAPTPOLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8129546-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-8129546-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-06 US disclosed
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 US disclosed
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-03-31 US disclosed
US-7842819-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 US disclosed
US-7842819-B2 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-11-30 US disclosed
US-20070203122-A1 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-08-30 US disclosed
US-20070203122-A1 Derivatives for modulation of ion channels VERTEX PHARMACEUTICALS INCORPORATED 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203122-A1 Derivatives for modulation of ion channels TRPV1, TRPA1, TRPV2 TDP1 4518/4885RAB9A 2235/4885KMT2A 2455/4885
US-20110077269-A1 DERIVATIVES FOR MODULATION OF ION CHANNELS TRPV1, TRPA1, TRPV2 TDP1 4518/4885RAB9A 2235/4885KMT2A 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.